OxibendazoleCAS# 20559-55-1 |
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- Nelarabine
Catalog No.:BCC1072
CAS No.:121032-29-9
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Clofarabine
Catalog No.:BCC1078
CAS No.:123318-82-1
- Ifosfamide
Catalog No.:BCC1164
CAS No.:3778-73-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 20559-55-1 | SDF | Download SDF |
PubChem ID | 4622 | Appearance | Powder |
Formula | C12H15N3O3 | M.Wt | 249.27 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 2.5 mg/mL (10.03 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | methyl N-(6-propoxy-1H-benzimidazol-2-yl)carbamate | ||
SMILES | CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC | ||
Standard InChIKey | RAOCRURYZCVHMG-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Oxibendazole Dilution Calculator
Oxibendazole Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.0117 mL | 20.0586 mL | 40.1171 mL | 80.2343 mL | 100.2929 mL |
5 mM | 0.8023 mL | 4.0117 mL | 8.0234 mL | 16.0469 mL | 20.0586 mL |
10 mM | 0.4012 mL | 2.0059 mL | 4.0117 mL | 8.0234 mL | 10.0293 mL |
50 mM | 0.0802 mL | 0.4012 mL | 0.8023 mL | 1.6047 mL | 2.0059 mL |
100 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 0.8023 mL | 1.0029 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxibendazole
- Pterocarpadiol D
Catalog No.:BCN7760
CAS No.:2055882-23-8
- Pterocarpadiol C
Catalog No.:BCN7759
CAS No.:2055882-22-7
- Pterocarpadiol A
Catalog No.:BCN7758
CAS No.:2055882-21-6
- Pterocarpadiol B
Catalog No.:BCN7757
CAS No.:2055882-20-5
- Faradiol
Catalog No.:BCN3795
CAS No.:20554-95-4
- Parthenolide
Catalog No.:BCN4896
CAS No.:20554-84-1
- 2'',4''-Di-O-(Z-p-coumaroyl)afzelin
Catalog No.:BCN4676
CAS No.:205534-17-4
- Fenfangjine G
Catalog No.:BCN3297
CAS No.:205533-81-9
- Fmoc-D-Phe(4-I)-OH
Catalog No.:BCC3262
CAS No.:205526-29-0
- Fmoc-D-Phe(3-Cl)-OH
Catalog No.:BCC3170
CAS No.:205526-23-4
- Rauvovertine A
Catalog No.:BCN7728
CAS No.:2055073-75-9
- Rauvovertine C
Catalog No.:BCN7727
CAS No.:2055073-74-8
- alpha-Solanine
Catalog No.:BCN2701
CAS No.:20562-02-1
- alpha-Chaconine
Catalog No.:BCN2162
CAS No.:20562-03-2
- Orexin A (human, rat, mouse)
Catalog No.:BCC5764
CAS No.:205640-90-0
- Orexin B (human)
Catalog No.:BCC5765
CAS No.:205640-91-1
- SB273005
Catalog No.:BCC6501
CAS No.:205678-31-5
- Calycosin
Catalog No.:BCN5930
CAS No.:20575-57-9
- Oxytetracycline hydrochloride
Catalog No.:BCC9110
CAS No.:2058-46-0
- H-D-Asn-OH.H2O
Catalog No.:BCC2879
CAS No.:2058-58-4
- Tetrahydromagnolol
Catalog No.:BCN8255
CAS No.:20601-85-8
- Ergosterol peroxide
Catalog No.:BCN4897
CAS No.:2061-64-5
- Tenofovir hydrate
Catalog No.:BCC4261
CAS No.:206184-49-8
- CB30865
Catalog No.:BCC1457
CAS No.:206275-15-2
Ultrastructural changes in Ascaris suum after oxibendazole treatment.[Pubmed:17580993]
Afr J Health Sci. 1998 Feb;5(1):38-41.
The effect of Oxibendazole treatment on adult Ascaris suum was assessed using scanning and transmission electron microscopy. The changes included collapse of the lip papillae, rupture of buccal cavity cuticle, prolapse of the pharynx, degeneration of epithelial cells and erosion of microvilli. Theses changes may lead to impaired digestion and absorption of nutrients and cause cellular autolysis, resulting in the death of the worm.
Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010).[Pubmed:21499750]
Parasitol Res. 2011 Oct;109(4):1193-7.
The activity of three anthelmintics (fenbendazole-FBZ; Oxibendazole-OBZ; and pyrantel pamoate-PRT) was ascertained against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010) in field tests. A total of 316 foals were treated, and 168 (53.2%) were passing ascarid eggs on the day of treatment. Evaluation of drug efficacy was determined qualitatively by comparing the number of foals passing ascarid eggs in their feces before and after treatment. The main purpose was to obtain data on current activity of these compounds against ascarids. Additionally, the objective was to compare these findings with those from earlier data on the efficacy of these three compounds on nematodes in foals in this geographical area. Efficacies (average) for the foals ranged for FBZ (10 mg/kg) from 50% to 100% (80%), for OBZ (10 mg/kg) from 75% to 100% (97%), and for PRT at 1x (6.6 mg base/kg) from 0% to 71% (2%) and at 2x (13.2 mg base/kg) 0% to 0% (0%). Although the efficacy varied among the drugs, combined data for all farms indicated a significant reduction of ascarid infections for FBZ (p < 0.0001) and OBZ (p < 0.0001) but not for PRT (p = 0.0953).
Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007.[Pubmed:18470536]
Parasitol Res. 2008 Jul;103(2):287-91.
Horse foals on five farms in Central Kentucky were used in field studies in 2007 evaluating activity of paste formulations of four compounds (fenbendazole-FBZ, ivermectin-IVM, Oxibendazole-OBZ, and pyrantel pamoate-PRT) against internal parasites with emphasis on ascarids (Parascaris equorum). It has been well established the last few years that there is widespread resistance of P. equorum to ivermectin. The main purpose of the present research was to obtain current data on ascaridicidal activity of FBZ, OBZ, and PRT; also, to acquire further information on ascarid resistance to ivermectin. Additionally, data were documented on drug activity on small strongyles. Detection of ascarid and strongyle eggs in feces of foals was by a qualitative method (presence or absence) or a quantitative method (eggs per gram of feces). Strongyle eggs all were assumed to be from small strongyles. This is based on fecal cultures from horses on one farm and historic records from horses in this area on excellent deworming programs. A girth tape was used to estimate the body weight of each foal so that the appropriate dose rate of each drug could be given. Many of the foals were used in more than one cycle of treatments. Efficacy of the drugs, administered intraorally, was determined by calculating the average percentage reduction (% red.) of the number of foals passing eggs after vs. before treatment: (1) FBZ at 10 mg/kg was tested on four farms; 76 foals were examined, 50 with ascarid eggs (84% red.) and 62 with strongyle eggs (0% red.); (2) IVM at 200 microg/kg was tested on three farms; 58 foals were examined, 18 with ascarid eggs (0% red.) and 48 with strongyle eggs (100% red.); (3) OBZ at 10 mg/kg was tested on three farms; 181 foals were examined, 78 with ascarid eggs (94% red.) and 79 with strongyle eggs (0% red.); (4) PRT was tested on two farms, one farm at 1x (6.6 mg base/kg); 42 were foals examined, 16 with ascarid eggs (0% red.) and 33 with strongyle eggs (12% red.) and one farm at 2x (13.2 mg base/kg); 18 foals were examined, 13 with ascarid eggs (23% red.) and 15 with strongyle eggs (27% red.).
Species-specific identification of equine cyathostomes resistant to fenbendazole and susceptible to oxibendazole and moxidectin by macroarray probing.[Pubmed:18950625]
Exp Parasitol. 2009 Jan;121(1):92-5.
Cyathostome populations in horses on two farms located in central Italy with a history of fenbendazole (FBZ) resistance were investigated with the Faecal Egg Count Reduction Test to evaluate the susceptibility to Oxibendazole and moxidectin. Faecal eggs were collected pre- and post-treatment on each farm and molecularly examined with a Reverse Line Blot (RLB) assay able to unequivocally detect and identify 13 cyathostome species. Resistance to FBZ was confirmed on both farms, while Oxibendazole and moxidectin demonstrated 97% and 100% efficacy, respectively. Overall eight species of cyathostomes (Coronocyclus labiatus, Cylicocyclus ashworthi, Cylicocyclus nassatus, Cyathostomum catinatum, Cylicostephanus longibursatus, Cylicostephanus goldi, Cylicostephanus calicatus and Cylicocyclus insigne) were identified in pre-treatment samples. Coronocyclus labiatus and C. goldi were identified after treatment with FBZ while C. calicatus and C. labiatus were shown to be <100% susceptible to Oxibendazole. These data confirm that resistance to benzimidazoles is established in cyathostome populations from horse farms in Italy and that they are susceptible to moxidectin. The Oxibendazole has been successfully demonstrated for the first time as effective against Italian populations of cyathostomes resistant to other benzimidazoles. The RLB assay herein used showed to be useful to study the distribution of these parasitic populations at species level under field conditions and could represent a powerful tool in broader investigation of drug resistance in horse farms from several countries.